BACKGROUND: Malignant pleural mesothelioma (MPM) treated with radiotherapy (RT) has incomplete responses as a result of radiation-induced tumoral stress response that repairs DNA damage. Such stress response is beneficial for oncolytic viral therapy. We hypothesized that a combination of RT and NV1066, an oncolytic herpes virus, might exert an additive or synergistic effect in the treatment of MPM. METHODS: JMN, a MPM cell line, was infected with NV1066 at multiplicities of infection of .05 to .25 in vitro with and without radiation (1 to 5 Gy). Virus replication was determined by plaque assay, cell kill by lactate dehydrogenase assay, and GADD34 (growth arrest and DNA damage repair 34, a DNA damage-repair protein) by real-time reverse transcriptase-polymerase chain reaction and Western blot test. Synergistic cytotoxicity dependence on GADD34 upregulation was confirmed by GADD34 small inhibitory RNA (siRNA). RESULTS: Synergism was demonstrated between RT and NV1066 across a wide range of doses. As a result of such synergism, a dose-reduction for each agent (up to 5500-fold) can be accomplished over a wide range of therapeutic-effect levels without sacrificing tumor cell kill. This effect is correlated with increased GADD34 expression and inhibited by transfection of siRNA directed against GADD34. CONCLUSIONS: RT can be combined with oncolytic herpes simplex virus therapy in the treatment of malignant pleural mesothelioma to achieve synergistic efficacy while minimizing dosage and toxicity.
BACKGROUND:Malignant pleural mesothelioma (MPM) treated with radiotherapy (RT) has incomplete responses as a result of radiation-induced tumoral stress response that repairs DNA damage. Such stress response is beneficial for oncolytic viral therapy. We hypothesized that a combination of RT and NV1066, an oncolytic herpes virus, might exert an additive or synergistic effect in the treatment of MPM. METHODS: JMN, a MPM cell line, was infected with NV1066 at multiplicities of infection of .05 to .25 in vitro with and without radiation (1 to 5 Gy). Virus replication was determined by plaque assay, cell kill by lactate dehydrogenase assay, and GADD34 (growth arrest and DNA damage repair 34, a DNA damage-repair protein) by real-time reverse transcriptase-polymerase chain reaction and Western blot test. Synergistic cytotoxicity dependence on GADD34 upregulation was confirmed by GADD34 small inhibitory RNA (siRNA). RESULTS: Synergism was demonstrated between RT and NV1066 across a wide range of doses. As a result of such synergism, a dose-reduction for each agent (up to 5500-fold) can be accomplished over a wide range of therapeutic-effect levels without sacrificing tumor cell kill. This effect is correlated with increased GADD34 expression and inhibited by transfection of siRNA directed against GADD34. CONCLUSIONS: RT can be combined with oncolytic herpes simplex virus therapy in the treatment of malignant pleural mesothelioma to achieve synergistic efficacy while minimizing dosage and toxicity.
Authors: Kathryn Ottolino-Perry; Jean-Simon Diallo; Brian D Lichty; John C Bell; J Andrea McCart Journal: Mol Ther Date: 2009-12-22 Impact factor: 11.454
Authors: S Gholami; C-H Chen; S Gao; E Lou; S Fujisawa; J Carson; J E Nnoli; T-C Chou; J Bromberg; Y Fong Journal: Cancer Gene Ther Date: 2014-06-13 Impact factor: 5.987
Authors: Nanhai Chen; Qian Zhang; Yong A Yu; Jochen Stritzker; Peter Brader; Andreas Schirbel; Samuel Samnick; Inna Serganova; Ronald Blasberg; Yuman Fong; Aladar A Szalay Journal: Mol Med Date: 2009-02-25 Impact factor: 6.354
Authors: Peter Brader; Kaitlyn J Kelly; Nanhai Chen; Yong A Yu; Qian Zhang; Pat Zanzonico; Eva M Burnazi; Rashid E Ghani; Inna Serganova; Hedvig Hricak; Aladar A Szalay; Yuman Fong; Ronald G Blasberg Journal: Clin Cancer Res Date: 2009-05-26 Impact factor: 12.531
Authors: S J Advani; J M Markert; R F Sood; S Samuel; G Y Gillespie; M Y Shao; B Roizman; R R Weichselbaum Journal: Gene Ther Date: 2011-05-05 Impact factor: 5.250